- Home
- Products
Mektovi (Binimetinib)
Mektovi (Binimetinib)
- Medicine Name: Mektovi
- Generic Name: Binimetinib
- Dosage Form & Strength: Tablets – 15 mg
- Manufactured By: Array BioPharma Inc.
Mektovi is a kinase inhibitor used in combination with encorafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Recommended Dosage:
- 45 mg orally twice daily (approximately 12 hours apart) with or without food
- Taken continuously in combination with encorafenib until disease progression or unacceptable toxicity
Administration Notes:
- Do not take a missed dose within 6 hours of the next scheduled dose
- If vomiting occurs, do not take an additional dose; resume with next scheduled dose
- Confirm BRAF V600E or V600K mutation before initiating therapy
- Cardiomyopathy: Monitor left ventricular ejection fraction (LVEF) before starting, 1 month after, then every 2–3 months
- Venous Thromboembolism (VTE): Includes pulmonary embolism. Adjust treatment based on severity
- Serous Retinopathy: Monitor visual symptoms regularly; refer for ophthalmic exams as needed
- Retinal Vein Occlusion (RVO): Discontinue permanently if diagnosed
- Uveitis: Perform eye assessments regularly, especially if symptoms develop
- Interstitial Lung Disease (ILD): Monitor for unexplained respiratory symptoms. Adjust dosage or discontinue as needed
- Hepatotoxicity: Monitor liver function tests monthly. Manage dosage based on severity
- Rhabdomyolysis: Monitor CPK and creatinine before and during treatment
- Reproductive Risk: Can cause fetal harm. Use effective contraception during and for 30 days after treatment
Documents Required for Import:
- Valid prescription from a qualified physician
- Patient’s diagnostic reports
- Government-issued ID proof
Order Confirmation:
- Orders are processed upon receiving valid documents and, if needed, an import permit
Availability in India: Mektovi is available in India through Global Rare Meds under the Named Patient Supply (NPS) program. We support patient access in cities including Mumbai, Delhi, Bangalore, Pune, Kolkata, Chennai, Ahmedabad, and more.
For Price & Ordering:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Mektovi from authorized international suppliers across the US, Canada, Europe, and Australia. All prescriptions are verified and fulfilled by registered pharmacists from our distribution hub in Ambernath, Thane District, India.
Timely and compliant delivery to patients worldwide is our top priority.
What is the generic name of Mektovi®?
Binimetinib
Who manufactures Mektovi®?
Array BioPharma Inc.
Is Mektovi® FDA approved?
Yes. Approved on June 27, 2018
What dosage form is Mektovi® supplied in?
Tablets – 15 mg for oral administration
What are the common side effects?
Fatigue, nausea, vomiting, diarrhea, and abdominal pain (in combination with encorafenib)
What is the price of Mektovi® in India?
Pricing varies. Contact us via WhatsApp at +91-99675 15602 or email info@globalraremeds.com
How should Mektovi® be stored?
Store at 20°C to 25°C (68°F to 77°F); excursions allowed between 15°C and 30°C (59°F to 86°F)
Can I buy Mektovi® online in India?
Yes. Global Rare Meds ensures legal, safe procurement of Mektovi for eligible patients under proper prescription
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
